Pilot study of the safety and efficacy of angiogenic therapy in diabetic foot syndrome

BACKGROUND: The syndrome of diabetic foot remains the main cause of non-traumatic amputation of the lower extremity in the world. Even with the provision of comprehensive medical care in the conditions of a specialized center, 10-15% of patients do not succeed in healing the ulcerative defect due to the ischemic component.

AIMS: The objective of this study is evaluation of safety and efficacy of pl-VEGF165 transfer in patients with neuroischemic type of diabetic foot syndrome.

METHODS: The pilot study included 35 diabetic patients with neuroischemic foot ulcers (Wagner stage 1-2) who were not candidates for revascularization procedures (NCT02538705). The patients were closely monitored after repeated pl-VEGF165 intramuscular gene transfer (2,4 mg) at 1, 3, and 6 months after treatment. The primary efficacy endpoint was the surface area of the ulcers (sq.cm), the secondary endpoints were transcutaneous oxygen tension (Tcp02), ankle-brachial index (ABI), neuropathy disability score (NDS), neuropathy symptoms score (NSS), and Michigan neuropathy screening instrument (MNSI). Adverse events were monitored throughout the study.

RESULTS: The use of pl-VEGF165 as part of complex treatment allowed to achieve wound healing in 65,7% of patients with chronic ulcerative defects, the safety of the target limb was 84%. Carrying out therapeutic angiogenesis as a part of the combined therapy ensured a reduction in the average area of the resistant to treatment defects from 3.6 [1.0; 7.05] cm² to 0.0 [0.0;2.0] cm² (p=0,001), which correlated with an increase in the TcPo2 index by 15% from 35 [29.5; 40.5] to 40.5 [36.0; 46.5] mm Hg (p= p=0,005) and in the ABI by 16% from 0.96 [0.82;1.08] to 1.11 [0.85; 1.24] (p=0,062). The decrease in the signs of diabetic neuropathy was determined - the scores of NSS scales and VAT decreased from 6,5 [5.75; 8.0) to 6.0 [5.25; 7.0] (p=0,004) and from 9.0 [8.0; 13.5] to 8.0 [7.0; 12.7] (p=0,001), respectively. No adverse effects associated with the use of pl-VEGF165 were recorded.

CONCLUSIONS: Thus, preliminary results of the pilot study show that the use of pl-VEGF165 gene transfer in combination therapy allows for complete healing of neuroischemic diabetic foot ulcers in the majority of patients.

diabetic foot syndrome, therapeutic angiogenesis, pl-VEGF165

1. Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006;45(5 Suppl):S1−66. doi: https://doi.org/10.1016/S1067-2516(07)60001-5

2. Green MF, Aliabadi Z, Green BT. Diabetic foot: evaluation and management. South Med J. 2002;95(1):95−101. doi: https://doi.org/10.1097/00007611-200201000-00019

3. Галстян Г.Р., Сергеева С.В., Игнатьева В.И., и др. Клинико-экономическое обоснование стоимости квоты на лечение пациентов с синдромом диабетической стопы // Сахарный диабет. — 2013. — №3. — С. 71–83. [Galstyan GR, Sergeeva SV, Ignat’eva VI, et al. Clinical and economical grounds of budgetary quotation for patients with diabetic foot syndrome. Diabetes Mellitus. 2013;(3):71–83. (In Russ.)] doi: https://doi.org/10.14341/2072-0351-820

4. Deev R, Bozo I, Mzhavanadze N, et al. pCMV-vegf165 intramuscular gene transfer is an effective method of treatment for patients with chronic lower limb ischemia. J Cardiovasc Pharmacol Ther. 2015;20(5):473−482. doi: https://doi.org/10.1177/1074248415574336

5. Деев Р.В., Калинин Р.Е., Червяков Ю.В., и др. Отдаленные результаты применения pl-VEGF165 при хронической ишемии нижних конечностей вследствие облитерирующего атеросклероза // Кардиология и сердечно-сосудистая хирургия. — 2015. — Т. 8. — №4. — С. 43−49. [Deev RV, Kalinin RE, Chervyakov YV, et al. Long-term results of pl-VEGF165 intramuscular gene transfer in patients with atherosclerotic chronic lower limb ischemia. Cardiology & cardiovascular surgery. 2015;8(4):43−49. (In Russ.)]

6. Saaristo A, Tammela T, Farkkila A, et al. Vascular endothelial growth factor-C accelerates diabetic wound healing. Am J Pathol. 2006;169(3):1080−1087. doi: https://doi.org/10.2353/ajpath.2006.051251

7. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res. 2009;105(8):724−736. doi: https://doi.org/10.1161/CIRCRESAHA.109.200386.

8. Галстян Г.Р., Токмакова А.Ю., Егорова Д.Н., и др. Клинические рекомендации по диагностике и лечению синдрома диабетической стопы // Раны и раневые инфекции. — 2015. — Т. 2. — №3. — С. 63−83. [Galstyan GR, Tokmakova AY, Egorova DN, et al. Clinical guidelines for diagnosis and treatment of diabetic foot syndrome. Wounds and wound infections. 2015;2(3):63–83. (In Russ.)]

9. Mulder G, Tallis AJ, Marshall VT, et al. Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): results of a phase 1/2 trial. Wound Repair Regen. 2009;17(6):772−779. doi: https://doi.org/10.1111/j.1524-475X.2009.00541.x

10. Phase 2b study of GAM501 in the treatment of diabetic ulcers of the lower extremities (MATRIX) [Internet]. ClinicalTrials.gov; 2020 [cited 2007 June 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT00493051

11. Safety and efficacy study of VM202 in the treatment of chronic non-healing foot ulcers [Internet]. ClinicalTrials.gov; 2020 [cited 2015 September 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02563522?term=VM202&rank=4

12. Deev R, Plaksa I, Bozo I, Isaev A. Results of an international postmarketing surveillance study of pl-VEGF165 safety and sufficacy in 210 satients with peripheral arterial disease. Am J Cardiovasc Drugs. 2017;17(3):235−242. doi: https://doi.org/10.1007/s40256-016-0210-3

13. Bolton LL. Quality randomized clinical trials of topical diabetic foot ulcer healing agents. Adv Wound Care (New Rochelle). 2016;5(3):137–147. doi: https://doi.org/10.1089/wound.2014.0571

14. Milne T, Schoen D, Bower V, et al. Times of diabetic foot ulcers: investigating the influence of infection and peripheral arterial disease. J Diabet Foot Compl. 2013;5(2):29−38.

15. Sheehan P, Jones P, Caselli A, et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 2003;26(6):1879−1882. doi: https://doi.org/10.2337/diacare.26.6.1879

16. Brownrigg JR, Hinchliffe RJ, Apelqvist J, et al. Performance of prognostic markers in the prediction of wound healing or amputation among patients with foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev. 2016;32 Suppl 1:128−135. doi: https://doi.org/10.1002/dmrr.2704

17. Ropper AH, Gorson KC, Gooch CL, et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: A randomized, double-blinded trial. Ann Neurol. 2009;65(4):386−393. doi: https://doi.org/10.1002/ana.21675

18. Ajroud-Driss S, Christiansen M, Allen JA, Kessler JA. Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy. Mol Ther. 2013;21(6):1279−1286. doi: https://doi.org/10.1038/mt.2013.69

19. Kessler JA, Smith AG, Cha BS, et al. Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy. Ann Clin Transl Neurol. 2015;2(5):465−478. doi: https://doi.org/10.1002/acn3.186